Therefore, Nidogen 1, Sphk1 and the type III TGF-β receptor could therefore serve as a novel theragnostic in AdCC, potentially in combination with an Akt- or NF-κB-inhibitor; respectively. Here, NID1 is linked to adrenocortical carcinoma, hereditary.